Epidermal Growth Factor Receptor Mutations as a Prognostic Factor in Korean Patients with Advanced Lung Adenocarcinoma Who Had Not Been Treated with Received Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

• Published in: Chemotherapy (Basel) Vol. 57; no. 2; pp. 108 - 114
• Main Authors: Kim, Seung Tae, Choi, Yoon Ji, Park, Kyong Hwa, Oh, Sang Cheul, Seo, Jae Hong, Shin, Sang Won, Kim, Jun Suk, Kim, Yeul Hong
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.01.2011
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Asian Continental Ancestry Group; Asian people; Chemotherapy; Clinical Study; Codon; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Exons; Female; Genes, erbB-1; Humans; Kinases; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Middle Aged; Mutation; Pharmacology; Protein Kinase Inhibitors - therapeutic use; Smoking; Epidermal growth factor receptor mutation; Tyrosine kinase inhibitors; Lung adenocarcinoma

Background: Epidermal growth factor receptor (EGFR) mutations as prognostic marker in patients with non-small cell lung cancers remain controversial. In particular, there is only a limited amount of data on the subject in Asian patients with advanced lung adenocarcinomas. Patients and Methods: We an...